IQVIA Holdings Inc. (NYSE:IQV) Receives $241.88 Consensus Target Price from Analysts

Posted by Casey Walker on Aug 2nd, 2026

Shares of IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $241.8824.

IQV has been the subject of a number of recent research reports. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Stifel Nicolaus boosted their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird increased their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday.

View Our Latest Research Report on IQVIA

IQVIA Trading Down 1.1%

Shares of NYSE IQV opened at $235.09 on Thursday. The company has a current ratio of 0.71, a quick ratio of 0.75 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average of $194.75 and a two-hundred day moving average of $187.20. IQVIA has a 1-year low of $154.50 and a 1-year high of $251.36. The company has a market cap of $38.70 billion, a PE ratio of 29.17, a P/E/G ratio of 1.99 and a beta of 1.20.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company earned $2.81 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts expect that IQVIA will post 11.61 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently modified their holdings of the stock. Apella Capital LLC increased its position in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 58 shares during the last quarter. Quadrant Capital Group LLC boosted its position in IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares during the last quarter. Brookstone Capital Management grew its stake in IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares in the last quarter. Private Advisor Group LLC increased its position in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the last quarter. Finally, Breakwater Capital Group raised its stake in shares of IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after purchasing an additional 64 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA News Roundup

Here are the key news stories impacting IQVIA this week:

Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

About IQVIA

(Get Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.